No Data
No Data
Earnings Preview: Genmab to Report Financial Results on November 06
Top Gap Ups and Downs on Tuesday: VFC, HSBC, F and More
Revitope Oncology Signs License Agreement Providing Genmab A/S Access To Revitope's Conditional TCE Technology, TwoGATE; Revitope Oncology To Receive Upfront Payment Of $9M With Milestone And Fee Payments Up To $600M Plus Tiered Single-Digit Royalties...
Revitope Enters Into a License Agreement for Next-generation T Cell Engagement Technology
Top Gap Ups and Downs on Thursday: TSM, BX, ELV and More
Genmab A/S (GMAB): Leading Innovation in Antibody Therapeutics
No Data
No Data